A Randomized, Open Label, Phase II Study of OSI-7904L Versus 5-FU/LV as First-Line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Adenocarcinoma of the Biliary Tract

NCT00088270 Phase 2 COMPLETED

Multi-center, randomized Phase II study to evaluate the efficacy and safety of OSI-7904Lversus 5 FU/LV in biliary tract cancer.

Details

Lead sponsor	OSI Pharmaceuticals
Phase	Phase 2
Status	COMPLETED
Enrolment	58
Start date	2004-08
Completion	2005-08

Conditions

• Locally Advanced or Metastatic Adenoca of the Biliary Tract

Interventions

• OSI-7904L
• 5-Fluorouracil/Leucovorin

Countries

United States, Belgium, Germany, Poland, Romania, Switzerland